| Ovol2 promoter mutations in mice and human illuminate species-specific phenotypic divergence. | Ovol2 promoter mutations in mice and human illuminate species-specific phenotypic divergence.
Sunny SS, Lachova J, Kasparek P, Palkova M, Spoutil F, Prochazka J, Sedlacek R, Liskova P, Kozmik Z. | 03/5/2024 |
| Transcriptional Repression of Aerobic Glycolysis by OVOL2 in Breast Cancer. | Transcriptional Repression of Aerobic Glycolysis by OVOL2 in Breast Cancer.
Zhang X, Luo F, Luo S, Li L, Ren X, Lin J, Liang Y, Ma C, Ding L, Zhang D, Ye T, Lin Y, Jin B, Gao S, Ye Q., Free PMC Article | 10/8/2022 |
| Altered Epithelial-mesenchymal Plasticity as a Result of Ovol2 Deletion Minimally Impacts the Self-renewal of Adult Mammary Basal Epithelial Cells. | Altered Epithelial-mesenchymal Plasticity as a Result of Ovol2 Deletion Minimally Impacts the Self-renewal of Adult Mammary Basal Epithelial Cells.
Sun P, Han Y, Plikus M, Dai X., Free PMC Article | 05/14/2022 |
| OVOL2 inhibits macrophage M2 polarization by regulating IL-10 transcription, and thus inhibits the tumor metastasis by modulating the tumor microenvironment. | OVOL2 inhibits macrophage M2 polarization by regulating IL-10 transcription, and thus inhibits the tumor metastasis by modulating the tumor microenvironment.
Wu RS, Lin J, Xing YM, Gao WL, Jiang YX, Chen LX, Zhang XP, Dai ZL. | 05/7/2022 |
| An NF-kappaB/OVOL2 circuit regulates glucose import and cell survival in non-small cell lung cancer. | An NF-κB/OVOL2 circuit regulates glucose import and cell survival in non-small cell lung cancer.
Zhang R, Geng GJ, Guo JG, Mi YJ, Zhu XL, Li N, Liu HM, Lin JF, Wang JW, Zhao G, Ye GZ, Li BA, Luo QC, Jiang J., Free PMC Article | 04/9/2022 |
| OVOL2 impairs RHO GTPase signaling to restrain mitosis and aggressiveness of Anaplastic Thyroid Cancer. | OVOL2 impairs RHO GTPase signaling to restrain mitosis and aggressiveness of Anaplastic Thyroid Cancer.
Gugnoni M, Manzotti G, Vitale E, Sauta E, Torricelli F, Reggiani F, Pistoni M, Piana S, Ciarrocchi A., Free PMC Article | 04/9/2022 |
| Dysregulation of the Pdx1/Ovol2/Zeb2 axis in dedifferentiated beta-cells triggers the induction of genes associated with epithelial-mesenchymal transition in diabetes. | Dysregulation of the Pdx1/Ovol2/Zeb2 axis in dedifferentiated β-cells triggers the induction of genes associated with epithelial-mesenchymal transition in diabetes.
de Jesus DS, Mak TCS, Wang YF, von Ohlen Y, Bai Y, Kane E, Chabosseau P, Chahrour CM, Distaso W, Salem V, Tomas A, Stoffel M, Rutter GA, Latreille M., Free PMC Article | 03/26/2022 |
| c.-61G>A in OVOL2 is a Pathogenic 5' Untranslated Region Variant Causing Posterior Polymorphous Corneal Dystrophy 1. | c.-61G>A in OVOL2 is a Pathogenic 5' Untranslated Region Variant Causing Posterior Polymorphous Corneal Dystrophy 1.
Janeschitz-Kriegl L, Kamdar D, Quinodoz M, Kaminska K, Folcher M, György B, Meyer P, Wild A, Escher P, Scholl HPN, Rivolta C, Goldblum D. | 02/5/2022 |
| OVOL2 attenuates the expression of MAP3K8 to suppress epithelial mesenchymal transition in colorectal cancer. | OVOL2 attenuates the expression of MAP3K8 to suppress epithelial mesenchymal transition in colorectal cancer.
Xia L, Gao J, Ma K, Lin H, Chen Y, Luo Q, Lian J. | 01/15/2022 |
| OVOL2 induces mesenchymal-to-epithelial transition in fibroblasts and enhances cell-state reprogramming towards epithelial lineages. | OVOL2 induces mesenchymal-to-epithelial transition in fibroblasts and enhances cell-state reprogramming towards epithelial lineages.
Watanabe K, Liu Y, Noguchi S, Murray M, Chang JC, Kishima M, Nishimura H, Hashimoto K, Minoda A, Suzuki H., Free PMC Article | 10/24/2020 |
| These findings suggest that alterations in the ZEB1-OVOL2-GRHL2 axis (caused by posterior polymorphous corneal dystrophy-associated mutations) lead to changes in corneal endothelial cell state and molecular pathways, including the aberrant activation of the Wnt signaling pathway. | Alterations in GRHL2-OVOL2-ZEB1 axis and aberrant activation of Wnt signaling lead to altered gene transcription in posterior polymorphous corneal dystrophy.
Chung DD, Zhang W, Jatavallabhula K, Barrington A, Jung J, Aldave AJ. | 02/22/2020 |
| TRPV1 is a potential therapeutic target in hepatocellular carcinoma and exerts effects on cellular plasticity with modulation of Ovol2, Zeb1 and Sox10. | Targeting TRPV1 on cellular plasticity regulated by Ovol 2 and Zeb 1 in hepatocellular carcinoma.
Xie C, Liu G, Li M, Fang Y, Qian K, Tang Y, Wu X, Lei X, Li X, Liu Q, Liu G, Liu J, Zhang Y, Huang Z, Hu Z, Cao Z, Hu J, Huang S, Zhong D, Huang J, Wu F, Wang J, Mori M, Yamamoto H, Wang J, Xu X. | 02/8/2020 |
| The function of OVOL2 as a tumor suppressor in vivo is highly regulated by PARylation. | Poly(ADP-ribosyl)ation of OVOL2 regulates aneuploidy and cell death in cancer cells.
Zhang R, Hong JJ, Yang Q, Ong CT, Li BA, Liou YC. | 05/4/2019 |
| OVOL2 only exhibits modest effect on epithelial-mesenchymal transition but has a strong impact on both metastasis and tumorigenesis. | OVOL2 links stemness and metastasis via fine-tuning epithelial-mesenchymal transition in nasopharyngeal carcinoma.
Qi XK, Han HQ, Zhang HJ, Xu M, Li L, Chen L, Xiang T, Feng QS, Kang T, Qian CN, Cai MY, Tao Q, Zeng YX, Feng L., Free PMC Article | 04/13/2019 |
| Taken together, this study suggests that the OVOL1-OVOL2 axis is a key modulator of c-Myc expression in the shift from in situ epidermal malignancy (Bowen's disease) to invasive squamous cell carcinoma. | Potential role of the OVOL1-OVOL2 axis and c-Myc in the progression of cutaneous squamous cell carcinoma.
Ito T, Tsuji G, Ohno F, Nakahara T, Uchi H, Furue M. | 04/14/2018 |
| OVOL2 antagonizes TGF-beta signaling to regulate epithelial to mesenchymal transition during mammary tumor metastasis. | OVOL2 antagonizes TGF-β signaling to regulate epithelial to mesenchymal transition during mammary tumor metastasis.
Wu RS, Hong JJ, Wu JF, Yan S, Wu D, Liu N, Liu QF, Wu QW, Xie YY, Liu YJ, Zheng ZZ, Chan EC, Zhang ZM, Li BA., Free PMC Article | 03/31/2018 |
| the OVOL2 promoter variant c.-307T>C was herein identified in the original family that established the posterior polymorphous corneal dystrophy 1 locus. | Confirmation of the OVOL2 Promoter Mutation c.-307T>C in Posterior Polymorphous Corneal Dystrophy 1.
Chung DD, Frausto RF, Cervantes AE, Gee KM, Zakharevich M, Hanser EM, Stone EM, Heon E, Aldave AJ., Free PMC Article | 08/12/2017 |
| hOvol2 expression was restricted to the XY body of spermatocytes at the pachytene stage. This study demonstrates that hOvol2 is expressed in germ cells and may be involved in spermatogenesis. | Expression of hOvol2 in the XY body of human spermatocytes.
Taniguchi H, Katano T, Nishida K, Yao I, Morimoto Y, Matsuda T, Ito S. | 02/18/2017 |
| OVOL2 maintains the transcriptional program of human corneal epithelium cells. | OVOL2 Maintains the Transcriptional Program of Human Corneal Epithelium by Suppressing Epithelial-to-Mesenchymal Transition.
Kitazawa K, Hikichi T, Nakamura T, Mitsunaga K, Tanaka A, Nakamura M, Yamakawa T, Furukawa S, Takasaka M, Goshima N, Watanabe A, Okita K, Kawasaki S, Ueno M, Kinoshita S, Masui S. | 02/18/2017 |
| Ovol2 can suppress migration and invasion ability of A549 cells, and prevent EMT by inhibition of Twist1 transcription directly. | Ovol2 gene inhibits the Epithelial-to-Mesenchymal Transition in lung adenocarcinoma by transcriptionally repressing Twist1.
Wang ZH, Li Z, Hu M, Yang QJ, Yan S, Wu RS, Li BA, Guo M. | 02/4/2017 |
| congenital hereditary endothelial dystrophy 1 (CHED1) and CHED2 loci on chromosome 20 and the collagen, type VIII, alpha-2 (COL8A2) gene were excluded by linkage and haplotype analyses. | Clinicopathologic correlation and genetic analysis in a case of posterior polymorphous corneal dystrophy.
Moroi SE, Gokhale PA, Schteingart MT, Sugar A, Downs CA, Shimizu S, Krafchak C, Fuse N, Elner SG, Elner VM, Flint A, Epstein MP, Boehnke M, Richards JE. | 01/26/2017 |
| We report the absence of a presumed pathogenic coding region mutation in the common PPCD1 support interval. | Exclusion of positional candidate gene coding region mutations in the common posterior polymorphous corneal dystrophy 1 candidate gene interval.
Aldave AJ, Yellore VS, Vo RC, Kamal KM, Rayner SA, Plaisier CL, Chen MC, Damani MR, Pham MN, Gorin MB, Sobel E, Papp J., Free PMC Article | 01/26/2017 |
| that the OVOL1-OVOL2 axis may actively contribute to cell differentiation and proliferation in the hair bulb | Activation of the OVOL1-OVOL2 Axis in the Hair Bulb and in Pilomatricoma.
Ito T, Tsuji G, Ohno F, Uchi H, Nakahara T, Hashimoto-Hachiya A, Yoshida Y, Yamamoto O, Oda Y, Furue M. | 09/10/2016 |
| OVOL2 is a colorectal tumor suppressor that blocks WNT signaling by facilitating the recruitment of histone deacetylase 1 to the TCF4-beta-catenin complex. | OVOL2, an Inhibitor of WNT Signaling, Reduces Invasive Activities of Human and Mouse Cancer Cells and Is Down-regulated in Human Colorectal Tumors.
Ye GD, Sun GB, Jiao P, Chen C, Liu QF, Huang XL, Zhang R, Cai WY, Li SN, Wu JF, Liu YJ, Wu RS, Xie YY, Chan EC, Liou YC, Li BA. | 07/16/2016 |
| data demonstrate that all four mutated OVOL2 promoters exhibited more transcriptional activity than the corresponding wild-type promoter | Autosomal-Dominant Corneal Endothelial Dystrophies CHED1 and PPCD1 Are Allelic Disorders Caused by Non-coding Mutations in the Promoter of OVOL2.
Davidson AE, Liskova P, Evans CJ, Dudakova L, Nosková L, Pontikos N, Hartmannová H, Hodaňová K, Stránecký V, Kozmík Z, Levis HJ, Idigo N, Sasai N, Maher GJ, Bellingham J, Veli N, Ebenezer ND, Cheetham ME, Daniels JT, Thaung CM, Jirsova K, Plagnol V, Filipec M, Kmoch S, Tuft SJ, Hardcastle AJ., Free PMC Article | 05/14/2016 |